Evidence map›Paper›PMID 28289967›Full record

Trial reportMolecular imaging and biology2017

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [

Ulka N Vaishampayan, Omid S Tehrani, Jawana M Lawhorn-Crews, Lance K Heilbrun, Kimberlee Dobson, Daryn Smith, Brenda Dickow, Anthony F Shields

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Exploring Solvent Effects in the Radiosynthesis ofACS pharmacology & translational science · 2021
    Article
  2. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ulka N VaishampayanKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA. vaishamu@karmanos.org.
Omid S TehraniUniversity of California San Francisco, Fresno, CA, USA.
Jawana M Lawhorn-CrewsKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Lance K HeilbrunKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Kimberlee DobsonKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Daryn SmithKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Brenda DickowKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Anthony F ShieldsKarmanos Cancer Institute, Wayne State University, 4233 Hudson Weber Cancer Center, 4100 John R, Detroit, MI, 48201, USA.
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · USUniversity of California, San Francisco · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
NCI NIH HHS P30 CA022453
6 · The paper itself

Abstract

purposeWe conducted a pilot trial utilizing [ PROCEDURES: Eligible patients had CRPC with radiographic evidence of BM and creatinine clearance >30 ml/min. Two baseline [

resultsEleven patients were evaluated, median age was 65 years, five were African-American and six were Caucasian, and median PSA level was 36.3 ng/ml (range 1.0-1209.3). Notably, the range of absolute percent SUVmax changes varied between 0.77 and 54.7, and only nine measurements were greater than one (1.09-2.19). Zoledronic acid did not appreciably change FMAU uptake. No clinical response was noted. Urine N-telopeptide (NTx) was markedly decreased in all patients after zoledronic acid and serum bone-specific alkaline phosphatase (BSAP) registered a modest change. Urine NTx correlated more closely with SUV max than serum BSAP.

conclusionsFMAU tracer was able to detect bone metastases in CRPC patients but uptake was highly variable in bony lesions. Zoledronic acid did not produce an appreciable change in scans. Future investigations of FMAU tracer as a marker of early response in CRPC is recommended.

Indexed as

Positron-Emission TomographyAgedArabinofuranosyluracilBiomarkers, TumorBone NeoplasmsBone RemodelingDiphosphonatesFluorine RadioisotopesHumansImage Processing, Computer-AssistedImidazolesMaleMiddle AgedPilot ProjectsProstate-Specific AntigenProstatic NeoplasmsArabinofuranosyluracilBiomarkers, TumorclevudineDiphosphonatesFluorine RadioisotopesImidazolesProstate-Specific AntigenZoledronic AcidCastrate resistant prostate cancerImagingPositron emission tomographyProstate-specific antigenZoledronic acid

Identifiers

PMID28289967
PMCPMC6844072
OpenAlexW2595997004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.